Modificare „Arbutus Biopharma Corporation”

Pagina dedicata companiei Arbutus Biopharma Corporation listata cu simbolul US.ABUS

==Descriere companie==
Arbutus Biopharma Corporation (http://www.arbutusbio.com/) is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.ABUS" />

==Ultimele stiri despre Arbutus Biopharma Corporation (US.ABUS)==
<dynamicpagelist>
category=US.ABUS
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.ABUS]][[Categorie:Stiri despre companii]]